TABLE 3.

New York Heart association functional classification before and after combination therapy

Patient number	BL1	3M	6M	BL2	3M2	6M2
1	III	III	III	III	III	III
2	III	III	II	III	III	III
3	III	II	II	II	II	II
4	III	III	III	III	III	III
5	III	III	II	II	I	I
6	II	I	II	II	II	II
7	III	III	III	III	II	II
8	II	II	II	II	II	II
9	III	II	II	II	II	II
10	II	I	II	III	II	II
Mean	2.70	2.30	2.30	2.50	2.20	2.20
±SD	0.48	0.82	0.48	0.53	0.63	0.63
±SE	0.15	0.26	0.15	0.17	0.20	0.20

BL1 Baseline 1 (before bosentan initiation); BL2 Baseline 2 (before initiation of bosentan plus sildenafil therapy); 3M Three months postinitiation of bosentan treatment; 3M2 Three months postinitiation of bosentan plus sildenafil treatment; 6M Six months postinitiation of bosentan treatment; 6M2 Six months postinitiation of bosentan plus sildenafil treatment